

Evaluation report

Day 1: Agenda

Time	Topic	Speakers
12:15–13:15	Arrivals and lunch	
13:15–13:30	Welcome to Spain	Ignacio Marín-Jiménez
13:30–13:40	Welcome, introductions and objectives: Day 1	Jean-Frédéric Colombel & Remo Panaccione
Raising standards of care		
13:40–14:00	PLENARY: Focus for standard of care today and in the future	Tim Raine
14:00–14:30	ROUNDTABLE: How can we improve standards of care in daily practice?	Led by Jean-Frédéric Colombel & Remo Panaccione with Raja Atreya, Peter Bossuyt, James Lindsay, Tim Raine, Joana Torres & Ryan Ungaro
14:30–14:40	Faculty Q&A	
Striving for better outcomes		
14:40–15:00	PLENARY: STRIDE-II and beyond – translating consensus recommendations into clinical practice	Peter Bossuyt & Tim Raine
15:00–15:30	Tea/coffee break	
15:30–16:15	WORKSHOP: Treating to target – what’s on your radar?	Peter Bossuyt, Subrata Ghosh & Tim Raine
16:15–16:45	PLENARY: Demystifying endpoints, targets and goals – from clinical trials to clinical practice	Krisztina Gecse & Reena Khanna
16:45–17:30	WORKSHOP: The real world – an interactive journey on monitoring patients and when to change treatment	Remo Panaccione, Krisztina Gecse & Subrata Ghosh
17:30–18:00	Q&A, summary and close	Remo Panaccione & Krisztina Gecse
18:00–18:05	Geographical highlights of Barcelona	Ignacio Marín-Jiménez
Dinner	Keynote speaker Future horizons: Precision medicine in IBD – fact or fiction?	Stephen Laroux (AbbVie, Precision Medicine) & Valerie Pivorunas (AbbVie, Precision Medicine)

Day 2: Agenda

Time	Topic	Speakers
Future outcomes and monitoring		
08:00–08:10	Welcome, introductions and objectives: Day 2	Jean-Frédéric Colombel & Remo Panaccione
08:10–08:30	PLENARY: State-of-the-art techniques for non-invasive monitoring in IBD	Joana Torres & Ryan Ungaro
08:30–09:15	WORKSHOP: Optimising approaches to monitoring in IBD	Joana Torres & Ryan Ungaro with Stephen Laroux & Valerie Pivorunas
IBD immunological pathway developments and the impact on clinical practice		
09:15–09:45	PLENARY: Targeting new immune pathways in IBD	Raja Atreya & James Lindsay
09:45–10:15	WORKSHOP: Piecing together the pathophysiology of IBD	All faculty, led by Raja Atreya & James Lindsay
10:15–10:35	Tea/coffee break	
10:35–11:35	PLENARY: New horizons in IBD treatments – an interactive discussion	Jean-Frédéric Colombel & Remo Panaccione
11:35–12:35	WORKSHOP: Interactive patient case studies – retracing our steps on the path to healing	Led by Subrata Ghosh with Reena Khanna & Joana Torres
12:35–12:55	Panel Q&A	All faculty
12:55–13:00	Close	Jean-Frédéric Colombel & Remo Panaccione with Ignacio Marín-Jiménez
13:00	Lunch and departures	

Objectives



Burden of IBD and importance of timely treatment

Relate the **high burden of disease** with the need for **timely treatment** in IBD with the aim of **optimising patient-centred outcomes**



Treatment goals and monitoring

Understand and advocate for **tight control** and **monitoring**, aiming for **mucosal healing** as a long term goal, as the **SoC** for the management of IBD, and be able to routinely apply consensus recommendations in clinical practice



Immunological pathways involved within the pathogenesis of IBD

Describe at least three **immunological pathways** (TNF, IL-23, JAK) involved in the **pathogenesis** of IBD and apply this knowledge to **understand the potential impact** for patients with IBD

The chairs



Professor Jean-Frédéric Colombel

Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, USA



Professor Remo Panaccione

Professor of Medicine and Director of the
Inflammatory Bowel Disease Unit
University of Calgary, Canada

Highlights



A global attendance

- Argentina



- Austria



- Bahrain



- Belgium



- Brazil



- Canada



- Colombia



- Croatia



- Estonia



- Germany



- Ireland



- Mexico



- Netherlands



- Portugal



- Qatar



- Saudi Arabia



- Slovenia



- Spain



- Switzerland



- United Arab Emirates



- United Kingdom



- Uruguay



- USA



Overall experience and general satisfaction

77% rated the overall quality of the programme as 'excellent'

68% strongly agreed that what they had learned has practical applications in their daily practice


100% were likely to recommend the programme to a colleague

72% strongly agreed that the content of the programme was appropriately aligned to the objectives


Programme objectives




On a scale of 1-5, where 1 is 'could be improved' and 5 is 'excellent', please rate your current level of knowledge of **the burden of disease in IBD and rationale for timely treatment**



On a scale of 1-5, where 1 is 'could be improved' and 5 is 'excellent', please rate your current level of knowledge of **tight control and monitoring for patients with IBD**



On a scale of 1-5, where 1 is 'could be improved' and 5 is 'excellent', please rate your current level of knowledge of **immunological pathways in IBD (e.g. TNF, IL-23 and JAK-STAT)** and how these relate to treatment options for patients with IBD




Speakers


abbvie




On a scale of 1-5, where 1 is 'strongly disagree' and 5 is 'strongly agree', please rate to what extent you agree that **Ignacio Marín-Jiménez's presentations 'Welcome to Spain' and 'Geographical highlights of Barcelona' were engaging and of high quality**




On a scale of 1-5, where 1 is 'strongly disagree' and 5 is 'strongly agree', please rate to what extent you agree that **Tim Raine's plenary 'Focus for standard of care today and in the future' was engaging and of high quality**




On a scale of 1-5, where 1 is 'strongly disagree' and 5 is 'strongly agree', please rate to what extent you agree that **Peter Bossuyt and Tim Raine's plenary 'STRIDE-II and beyond – translating consensus recommendations into clinical practice' was engaging and of high quality**




On a scale of 1-5, where 1 is 'strongly disagree' and 5 is 'strongly agree', please rate to what extent you agree that **Krisztina Gecse and Reena Khanna's plenary 'Demystifying endpoints, targets and goals – from clinical trials to clinical practice' was engaging and of high quality**




On a scale of 1-5, where 1 is 'strongly disagree' and 5 is 'strongly agree', please rate to what extent you agree that **Stephen Laroux and Valerie Pivorunas' keynote speaker presentation 'Future horizons: Precision medicine in IBD – fact or fiction?' was engaging and of high quality**




On a scale of 1-5, where 1 is 'strongly disagree' and 5 is 'strongly agree', please rate to what extent you agree that **Joana Torres and Ryan Ungaro's plenary 'State-of-the-art-techniques for non-invasive monitoring in IBD' was engaging and of high quality**



On a scale of 1-5, where 1 is 'strongly disagree' and 5 is 'strongly agree', please rate to what extent you agree that **Raja Atreya and James Lindsay's plenary 'Targeting new immune pathways in IBD' was engaging and of high quality**




On a scale of 1-5, where 1 is 'strongly disagree' and 5 is 'strongly agree', please rate to what extent you agree that **Jean-Frédéric Colombel and Remo Panaccione's plenary 'New horizons in IBD treatments – an interactive discussion' was engaging and of high quality**




Workshops




On a scale of 1-5, where 1 is 'strongly disagree' and 5 is 'strongly agree', please rate to what extent you agree that the roundtable **'How can we improve standards of care in daily practice?'** was engaging and interesting




On a scale of 1-5, where 1 is 'strongly disagree' and 5 is 'strongly agree', please rate to what extent you agree that the workshop **'Treating to target – what's on your radar?' generated great discussion between me and my colleagues**




On a scale of 1-5, where 1 is 'strongly disagree' and 5 is 'strongly agree', please rate to what extent you agree that the workshop **'The real world – an interactive journey on monitoring patients and when to change treatment' allowed me to apply knowledge from the plenary to a real-world scenario**



On a scale of 1-5, where 1 is 'strongly disagree' and 5 is 'strongly agree', please rate to what extent you agree that the workshop the workshop **'Optimising approaches to monitoring in IBD' workshop made me consider my monitoring strategies**



On a scale of 1-5, where 1 is 'strongly disagree' and 5 is 'strongly agree', please rate to what extent you agree that the workshop the workshop **'Piecing together the pathophysiology of IBD' helped me understand the immunopathogenesis of IBD in the context of investigational treatments**



On a scale of 1-5, where 1 is 'strongly disagree' and 5 is 'strongly agree', please rate to what extent you agree that the workshop the workshop **'Interactive patient case studies – retracing our steps on the path to healing'** allowed me to apply the learnings from the programme to patient scenarios



Open feedback





‘Excellent workshops,
informative and helpful in
highlighting ways to
improve my IBD practice’

‘Nice combination
of different formats’

‘It was superb! Thank
you very much!’

‘Very good
clinical cases!’

‘Discussions and
opinions by faculty were
most valuable for me’

‘Very good programme’

‘Great format’

‘Great experience’



abbvie